Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Foghorn Therapeutics FY 2024 GAAP EPS $(1.58) Beats $(1.61) Estimate, Sales $22.602M Miss $30.713M Estimate

Author: Benzinga Newsdesk | March 06, 2025 05:14pm
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(1.61) by 1.86 percent. This is a 32.48 percent increase over losses of $(2.34) per share from the same period last year. The company reported quarterly sales of $22.602 million which missed the analyst consensus estimate of $30.713 million by 26.41 percent. This is a 33.83 percent decrease over sales of $34.155 million the same period last year.

Posted In: FHTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist